Collegium Pharmaceutical (NASDAQ:COLL) Stock Price Target Lowered at Piper Sandler

Collegium Pharmaceutical (NASDAQ:COLL) had its target price trimmed by Piper Sandler from $43.00 to $28.00 in a report published on Friday morning,Benzinga reports. The brokerage currently has a neutral rating on the specialty pharmaceutical company’s stock.

Other equities analysts also recently issued reports about the stock. Needham & Company LLC reduced their price objective on shares of Collegium Pharmaceutical from $46.00 to $44.00 and set a “buy” rating for the company in a report on Thursday. Wall Street Zen cut shares of Collegium Pharmaceutical from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. Weiss Ratings cut shares of Collegium Pharmaceutical from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Friday, September 4th. Jefferies Financial Group reissued a “buy” rating and issued a $35.00 price target on shares of Collegium Pharmaceutical in a research report on Friday. Finally, Zacks Research upgraded shares of Collegium Pharmaceutical from a “strong sell” rating to a “strong-buy” rating in a research note on Thursday, October 15th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $44.88.

Collegium Pharmaceutical Stock Performance

Shares of COLL stock traded down $0.95 during mid-day trading on Friday, reaching $24.21. The stock had a trading volume of 775,375 shares, compared to its average volume of 622,329. Collegium Pharmaceutical has a one year low of $21.43 and a one year high of $50.79. The firm has a market cap of $788.28 million, a PE ratio of 24.21, a P/E/G ratio of 0.74 and a beta of 0.75. The firm’s 50 day simple moving average is $22.99 and its 200 day simple moving average is $32.79. The company has a quick ratio of 0.84, a current ratio of 1.03 and a debt-to-equity ratio of 3.32.

Collegium Pharmaceutical (NASDAQ:COLL) last released its quarterly earnings data on Thursday, November 5th. The specialty pharmaceutical company reported $1.96 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.86 by $0.10. The business had revenue of $216.34 million for the quarter, compared to analysts’ expectations of $216.03 million. Collegium Pharmaceutical had a return on equity of 91.43% and a net margin of 5.93%. Collegium Pharmaceutical’s quarterly revenue was up 67.4% on a year-over-year basis. During the same period in the previous year, the business posted $2.25 earnings per share. On average, analysts forecast that Collegium Pharmaceutical will post 6.42 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Freestone Grove Partners LP bought a new stake in shares of Collegium Pharmaceutical in the 2nd quarter worth about $1,611,000. Globeflex Capital L P acquired a new stake in shares of Collegium Pharmaceutical during the 2nd quarter worth about $1,915,000. Bank of America Corp DE bought a new position in Collegium Pharmaceutical during the 2nd quarter valued at about $9,882,000. Empowered Funds LLC bought a new position in Collegium Pharmaceutical during the 2nd quarter valued at about $2,045,000. Finally, Bank of New York Mellon Corp bought a new position in Collegium Pharmaceutical during the 2nd quarter valued at about $8,506,000.

Collegium Pharmaceutical News Summary

Here are the key news stories impacting Collegium Pharmaceutical this week:

• Positive Sentiment: Q3 adjusted earnings of $1.96 per share topped consensus estimates, and revenue of $216.3 million narrowly beat expectations. The company reported record quarterly revenue, including JORNAY PM revenue up 24% year over year. Collegium Q3 2026 results
• Positive Sentiment: FY 2026 revenue guidance is $825 million–$855 million, a range whose midpoint is above the $832.9 million consensus estimate. Collegium also announced a $50 million accelerated share repurchase. Collegium Q3 2026 results
• Neutral Sentiment: Needham lowered its price target from $46 to $44 but maintained a Buy rating, indicating continued optimism alongside a more cautious valuation. Needham lowers Collegium price target
• Negative Sentiment: Piper Sandler cut its target sharply, from $43 to $28, and assigned a Neutral rating. The lower valuation outlook could weigh on sentiment despite the target remaining above the referenced share price. Piper Sandler rating
• Negative Sentiment: EPS declined from $2.25 in the year-ago quarter to $1.96, tempering the earnings beat. Collegium Q3 earnings

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on developing and commercializing medicines for pain management and central nervous system disorders. The company primarily serves the U.S. market and emphasizes products designed to address significant patient and healthcare-provider needs.

Its pain portfolio includes Xtampza ER, an extended-release oxycodone formulation designed with abuse-deterrent properties, as well as Nucynta and Nucynta ER, which contain tapentadol and are used to treat acute and chronic pain.